In all due respect, what do you view as new historical highs in 2016? The most recent highs of 17 pps or the real historical highs which are much higher?
Yes, SLXP trading at 9 times Revenues and 118 PE Ratio with $2 B in Debt. SPPI trading at a little over 3 times Revenue. 8 times existing Revenue would put SPPI in the $25 PPS range Today.
SPPI will likely have $250 MM in revenue run rate in 1st Half of 2016 approximately which is $33 PPS at an 8 multiple.
In 2016, SPI-2012, Apaziquone, Marquibo additional indications and the other 15 studies will also be coming to fruition many of which are $200 to $1B year type revenue generators. If any one or more of those hit, SPPI will be on the launching pad.
TORONTO, ON--(Marketwired - Jul 8, 2014) - Easton Pharmaceuticals (OTC: EAPH) announces corporate response to libelous seeking alpha article.
As a response to a second seeking alpha written by a Mr. Matt Finston, Easton Pharmaceuticals has entered in discussions to join with 1 to 2 other companies in a joint legal response to Matt Finston and articles written and posted by him on seeking alpha against Easton Pharmaceuticals and these other companys.
As disclosed in a prior press release, Easton Pharmaceuticals was the victim of a slanderous article by a Matt Finston of seeking alpha posted in March of 2014. It has now come to the company's attention that a second article attacking the company was once again posted today. The writer, Mr. Matt Finston and seeking alpha who normally only post or write on mid to large cap stocks, posted an article on the Company that was not only once again inaccurate, but made libelous allegations against its products and others involved in the company. The second article on Easton Pharmaceuticals, released this morning has once again been released after a recent uptrend in the companies trading stock. Both times the articles were followed by massive short or negative posts on many investor chat boards in an attempt to dis-credit the company. The most recent article goes to great lengths to cause as much damage as possible to the company which is thought by the company's attorney as well as by others to be out of the ordinary. As a response to this clear attempt to hurt shareholders and the companies attempt to grow its business, Easton believes it will soon join with other companies who have either sued Mr. Finston as a response to similar attacks or are in the process of launching lawsuits. Mr. Finston has not only repeatedly stated the incorrect cash position of the company, the wrong names for the company's directors, but has also posted the wrong names of products or posted that the company still owns."
That is about it. LOL. They will manipulate until they are ready. With only 63 million shares, SPPI is a perfect manipulation candidate to make money shorting and then buy more on the way up. Short again and make money and then double down on the way up. Rinse and repeat. Basically long but greedy on the short manipulation too. When any event causes them to go all long, look out!
No different than Al Qaida. One is legal and one is a terrorist. The war is on Cancer. If you attack it, you are attacking all of Mankind for your own self-serving monetary and power needs.
Rot in HELL.
1. Higher than $8.15 PPS close. By far.
2. If Positive SP-2012 Data which is a $5 B market, who knows but a lot of biotechs are at 8 to 10 times current revenues without any pipeline like SPPI.
3. I see no scenario where any SPPI buyout will be under $30 PPS irrespective of what the offer may be. If less, it will not be approved by the BOD. $30 PPS is $2 B at a minimum. Dont care if it takes one month or several years. irrelevant. Much to much to offer to sell for less.
Most of your friends were terminated by your "handlers and bosses". Here are the pathetic lonely survivors who are still willing to do anything to get their pennies a post.
What a pathetic life. Don't let them fool you. Not smart enough to earn a living the old fashion way. Their "handlers" 100% OWN these guys and gals:
Maxipad touted his new stock PCYC as the SPPI challenge on Sunday, June 29th:
SPPI up 8.9% - $8.01 to $8.72 PPS
PCYC up 5.3% this week. $88.43 to $93.13 PPS
BTW, let's see how it goes for 3 or 4 years. PCYC is a $6,7 B company already at SIXTEEN to SEVENTEEN TIMES Revenues and a FIFTY-TWO PE RATIO.
SPPI a little over a 3 multiple of Revenues. Severely undervalued with an extensive pipeline.
3.5 MILLION and 1.3 MILLION Shares. ACTUALLY $11,414,000 in AFTER HOURS BUYS at the close.
$20 PPS is 8 times current revenues. However, that is before the two layup FDA filings for Belinostat and Capistrol-enabled Melphalan.
Currently SPPI is so undervalued it is ridiculous.
SP 2012 is on the prowl and is a Gorilla in the Jungle. Be careful out there.
Bioshet what color did you paint your nails?
Yes, I did buy more yesterday. Who wouldn't when a biotech is trading at 2 times existing revenues plus cash on hand, which has:
1. $100 million in cash;
2. $180 million in existing revenues;
3. Its 5th FDA drug just approved with revenues which will be additive;
4. Has two more NDA's on the way in 2014 one of which is a slam dunk and will dominate a $130 M annual market and the other is likely to generate $200 million plus annually if approved;
5. Is essentially breakeven from an operating cash flow standpoint without regard to drug acquisition costs; and
6. Has many Billion dollar market opportunities in the Pipeline including SPI-2012 which is frontburner in an existing $6 Billion Annual Market.
LOL. From $6.60 UP to $8.90 since May in less than two months is hardly a "daytrading stock".
Also, it is 5 FDA approved drugs. Capistrol-enabled Melphalan will be the 6th.
Great analysis and comments ouch.
I think once SPPI has $250M in stable revenues and any positive SP-2012 or Apaz or SP-1620 or Marq data is released which reflect huge revenue market opportunities, there wil be a buyout offer which will likely be accepted even before there is an FDA approval of those blockbusters. Likely in 2016 sometime and in the $2.5 to $3.5 B range at $40 to $60 PPS.
With an approximate $180 million revenue run rate and CE-Melphalan coming on board in 2015 (which is almost certain), when do you expect SPPI's PPS to be at a mere 6 times revenues and $25 PPS. It would likely only be a mere 8 multiple by year-end.
Is it 2014, 2015 or 2016? TIA
1. Shorts can rot in HELL. You are shorting life and investing for death. Period. Godspeed on your journey. There is no ambiguity whatsoever.
2. Most important:
Look up KERX, OREX, DNDN, PCYC, AVNR and whomever else you want. This is a premeditated short attack on biotech premeditated with Janet Yellen. Do you think the author of the SA Article on SPPI knew what was coming? For sure.
Bought today. Bought relentlessly since $6 PPS. Will keep on doing so.